We continue to monitor the medical literature for developments related to gadolinium retention in connection with our investigation of cases of Gadolinium Deposition Disease (GDD) in patients who received injections of gadolinium based contrast agents for their MRI, MRA, or CT scan procedure.
Presented below is a collection of medical articles published in the past six months — September 2018 to March 2019 — written by or about medical researchers investigating the extent and severity of gadolinium retention following injections of gadolinium-based contrast agents for MRIs, MRAs, and CT scans.
- “Safety of Gadolinium Administration in Children”, from Pediatric Neurology medical journal (September 2018 edition) — Abstract
- “How widespread is gadolinium accumulation in the brain?”, an AuntMinnie.com news report (October 31, 2018) — Preview of November 28, 2018 scientific sessions at the annual RSNA show
- “Long-term Excretion of Gadolinium-based Contrast Agents: Linear versus Macrocyclic Agents in an Experimental Rat Model”, from Radiology medical journal (Published Online: November 13, 2018) — Abstract
- “Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents”, from Neuroradiology medical journal (First Online: February 2, 2019) — Abstract
For more about Gadolinium Deposition Disease (GDD) in patients, which is a form of gadolinium toxicity and sometimes called, instead, Gadolinium Storage Condition, see our Gadolinium Based Contrast Agents Side Effects page.[Read article in full at original source]